
Precision Biosciences (DTIL) Stock Forecast & Price Target
Precision Biosciences (DTIL) Analyst Ratings
Bulls say
Precision BioSciences Inc. is experiencing positive developments with its ARCUS genome editing platform, as evidenced by the successful progression of its partnered programs, which enhance its clinical potential across diverse disease settings. The company has two wholly-owned ARCUS-based programs that are gaining momentum backed by partner-led clinical validation, indicating strong advancements in their pipeline. Notably, preclinical results show treated mice achieving up to 93% of maximum force output and a 66% improvement in resistance to eccentric injury, suggesting significant therapeutic efficacy and reinforcing confidence in the platform's capabilities.
Bears say
Precision BioSciences Inc. has experienced a notable decrease in revenue, with cash and cash equivalents falling to approximately $100 million from the previously estimated $122 million. This decline is attributed to reduced revenue recognition from collaborations with Prevail/Lilly and Novartis, as both agreements progress towards conclusion and affect short-term financial contributions. Furthermore, the company’s reliance on a recent license agreement with TGTherapeutics for CAR T therapy indicates a dependency on external partnerships for sustaining revenue, raising concerns about long-term financial stability.
This aggregate rating is based on analysts' research of Precision Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Precision Biosciences (DTIL) Analyst Forecast & Price Prediction
Start investing in Precision Biosciences (DTIL)
Order type
Buy in
Order amount
Est. shares
0 shares